UNSPSC 51361915: Metharbital

This classification denotes a barbiturate with the molecular formula C9H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02OS7K758T, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-1-methyl- but generally known as metharbital, which bears US NIH Compound Identifier 4099. European Medicines Agency schedules Metharbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08841MIG. The term METHARBITAL is an International Non-Proprietary Name.

UNSPSC 51361915 Metharbital is a Commodity code that nominally designates a specific barbiturate pharmaceutical product, but recent state and local solicitations tagged with this code do not reflect procurement of metharbital itself. Instead, issuing bodies are using the code to acquire a broader mix of pharmaceutical and health-related products and services, including naloxone (an opioid antagonist), drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and pharmacy benefit program services. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multi-state and multi-jurisdictional government facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mismatch between the code's nominal scope and the actual work being solicited suggests either broad administrative tagging of pharmaceutical procurements under a single commodity code or upstream classification drift in state and local systems.

Recent opportunities reflect three distinct procurement models. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries and fixed pricing. The Texas HHS Commission released an RFI (Solicitation Number HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, focusing on alternative contracting models outside traditional pharmacy benefit managers and wholesalers. MMCAP, administered by Minnesota's Department of Administration, issued an RFP (Solicitation Number S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and DSCSA standards. Activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multi-state footprint extending into Oregon. The code shows sparse recent activity and a disconnect from its nominal pharmaceutical product scope, signaling limited relevance for vendors supplying metharbital specifically.